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parametric data. OLS regression tested the relationship
between duration of therapy and presence of CHD risk
factors. RESULTS: For each statin, days on therapy dif-
fered significantly (p  0.001) by the number of risk fac-
tors. The number of CHD risk factors was positively sig-
nificant in predicting duration of therapy (p  0.0001) in
both new and continuing therapy. Duration of therapy
was associated with an increase of 48 days for each risk
factor for new patients and 58 days for continuing pa-
tients.CONCLUSIONS: Number of CHD risk factors is
positively correlated with length of therapy when using
statins as lipid lowering therapy for new and continuing
patients.
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INTRODUCTION: Naturalistic studies are essential to
prospectively study real-world antihypertensive treat-
ment OBJECTIVE: to evaluate the feasibility of perform-
ing a naturalistic study in newly diagnosed hypertensives
in terms of enrollment, adequacy, timeliness of data col-
lection, and study procedures. METHODS: CHOICE
prospectively collected actual practice data on the treat-
ment of newly-diagnosed hypertensive patients. Initial
therapy was randomly assigned to either Group 1 (beta
blockers or diuretics) or Group 2 (ACE inhibitors or cal-
cium channel blockers). The protocol made no demands
in scheduling visits or changing treatment during follow-
up. Physicians were blind to study purpose and hypothe-
ses. Only a final visit at 5  1 months, if none occurred
naturally, was mandated. Direct involvement of the
CHOICE study team was minimized using a Remote
Study Monitoring System to collect data and communi-
cate with study sites. RESULTS: Within 30 weeks, a total
of 55 physicians enrolled 512 patients with a mean age of
51 years and blood pressure of 158/99 mmHG. In all, 46
different antihypertensive medications were prescribed
and 2,554 office visits (range  1–16 visits per patient)
were attended. Other medical resource use was low dur-
ing the study period. A final, clean database was ready
for analysis 30 days after last patient last visit. CON-
CLUSIONS: It has been demonstrated that CHOICE is a
Statin Risk Factors (RF): 0 RF: 1 RF: 2 RF: 3 OR 4
Overall Median 305 431 481 550
atorvastatin 345 419 424 562
fluvastatin 289 428 505 568
pravastatin 303 444 469 533
feasible framework to study the real-world effectiveness
of initial therapy for newly diagnosed hypertension. Pro-
tocol flexibility and a novel electronic data entry system
are core elements of this naturalistic design.
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Economic analysis of various treatment modalities used
to prevent deep vein thrombosis (DVT) in various medi-
cal and surgical at-risk patients has been limited by lack
of consistent and representative methods to evaluate vari-
ous resource costs attributed to both the prevention of
DVT and the diagnosis and treatment of prophylaxis fail-
ures. OBJECTIVE: To develop a systematic and compre-
hensive method to identify and prioritize all direct costs
associated with DVT prophylaxis. METHODS: A deci-
sion tree was developed to identify and prioritize all med-
ical, surgical and diagnostic procedures that contribute to
overall direct cost. Included were costs of prophylaxis,
cost of diagnosing a prophylaxis failure (a DVT) and
costs of major complications of this therapy (pulmonary
embolism, major bleeding and thrombocytopenia.) Diag-
nostic procedures were also prioritized clinically as either
a “standard”, “alternative or confirmatory”, or “supple-
mental” procedure. This prioritization allows for proba-
bility multipliers to be assigned to each category of diag-
nostic procedures in order to get a weighted average of
the cost of this procedure. Likewise, the various costs as-
sociated with prophylaxis failure were prioritized. Next a
spreadsheet was developed to match this decision tree.
This spreadsheet contained all identified resource costs
shown on the decision tree and indicated the quantity or
units of each resource that are typically used. Lastly, the
corresponding CPT and ICD9 codes for all resources
were identified. RESULTS: Major categories of resources
identified include diagnostic, treatment, and monitoring.
These 3 areas are divided into 13 sub-categories which in
turn include over 60 specifically identified cost related re-
sources. CONCLUSION: This model allows any institu-
tion to accurately identify, prioritize and analyze institu-
tion specific resource costs instead of using literature
values to determine the cost-benefit of various pharma-
coprophylactic regimens including unfractionated hep-
arin and various low molecular weight heparins used at
their site.
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